Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy.
作者信息
Shah Parth V, Arrieta Víctor A, Lee-Chang Catalina, Sonabend Adam M
机构信息
Department of Neurosurgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
PECEM, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
出版信息
J Cell Immunol. 2020;2(6):352-358. doi: 10.33696/immunology.2.066.
Abstract
摘要
相似文献
1
Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy.
J Cell Immunol. 2020;2(6):352-358. doi: 10.33696/immunology.2.066.
2
Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.
Expert Rev Anticancer Ther. 2011 Nov;11(11):1759-74. doi: 10.1586/era.11.102.
3
CD8 T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.
Clin Cancer Res. 2020 Aug 15;26(16):4390-4401. doi: 10.1158/1078-0432.CCR-19-3104. Epub 2020 May 19.
4
Therapeutic applications of the cancer immunoediting hypothesis.
Semin Cancer Biol. 2022 Jan;78:63-77. doi: 10.1016/j.semcancer.2021.03.002. Epub 2021 Mar 9.
5
From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology.
Adv Exp Med Biol. 2018;1092:113-138. doi: 10.1007/978-3-319-95294-9_7.
6
[Cancer Immunoediting in the Development of Cancer Immunotherapy].
Gan To Kagaku Ryoho. 2019 Mar;46(3):407-411.
7
Immunogenicity and Immune Silence in Human Cancer.
Front Immunol. 2020 Mar 6;11:69. doi: 10.3389/fimmu.2020.00069. eCollection 2020.
8
Exosomes in cancer immunoediting and immunotherapy.
Asian J Pharm Sci. 2022 Mar;17(2):193-205. doi: 10.1016/j.ajps.2021.12.001. Epub 2022 Jan 4.
9
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
Ann N Y Acad Sci. 2013 May;1284(1):1-5. doi: 10.1111/nyas.12105.
10
Cancer immunoediting and resistance to T cell-based immunotherapy.
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8.
引用本文的文献
1
Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.
Cancer Control. 2024 Jan-Dec;31:10732748241290067. doi: 10.1177/10732748241290067.
本文引用的文献
1
Glioma escape signature and clonal development under immune pressure.
J Clin Invest. 2020 Oct 1;130(10):5257-5271. doi: 10.1172/JCI138760.
2
cGAS-STING-mediated DNA sensing maintains CD8 T cell stemness and promotes antitumor T cell therapy.
Sci Transl Med. 2020 Jun 24;12(549). doi: 10.1126/scitranslmed.aay9013.
3
Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
Clin Cancer Res. 2020 Sep 1;26(17):4699-4712. doi: 10.1158/1078-0432.CCR-19-4110. Epub 2020 Jun 18.
4
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
Clin Cancer Res. 2020 Oct 1;26(19):5232-5245. doi: 10.1158/1078-0432.CCR-19-3874. Epub 2020 Jun 16.
5
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.
6
CD8 T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.
Clin Cancer Res. 2020 Aug 15;26(16):4390-4401. doi: 10.1158/1078-0432.CCR-19-3104. Epub 2020 May 19.
7
Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer.
Head Neck. 2020 Sep;42(9):2722-2733. doi: 10.1002/hed.26158. Epub 2020 Apr 10.
8
Monocytes and Macrophages in Cancer: Unsuspected Roles.
Adv Exp Med Biol. 2020;1219:161-185. doi: 10.1007/978-3-030-34025-4_9.
9
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
Neuro Oncol. 2020 Apr 15;22(4):539-549. doi: 10.1093/neuonc/noz185.
10
Longitudinal molecular trajectories of diffuse glioma in adults.
Nature. 2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20.
Zotero 插件